ArticlePloS one2017
Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 90 citations in OpenAlex.
- In Vitro Evaluation of Combination Therapy with Doxorubicin and Quercetin for Uveal Melanoma.Current issues in molecular biology · 2026Article
- Agro-Industrial Plant Biomass as a Sustainable Source of Anticancer Polyphenols: Molecular Mechanisms and Future Perspectives.Current issues in molecular biology · 2026Review
- Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin.Heliyon · 2025Review
- Multi-target mechanisms and potential applications of quercetin in the treatment of acne vulgaris.Frontiers in pharmacology · 2025Review
- Decoding Therapeutic Applications of Quercetin: Recent Advancements in Nanotechnological Strategies.Pharmaceutical nanotechnology · 2025Review
- Quercetin promotes the proportion and maturation of NK cells by binding to MYH9 and improves cognitive functions in aged mice.Immunity & ageing : I & A · 2024Article
- Levofloxacin and Ciprofloxacin Co-Crystals with Flavonoids: Solid-State Investigation for a Multitarget Strategy againstPharmaceutics · 2024Article
- Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms.Current medicinal chemistry · 2024Review
- Total Flavonoids inInternational journal of molecular sciences · 2023Article
- Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2023Review
- Naringenin and Quercetin Exert Contradictory Cytoprotective and Cytotoxic Effects on Tamoxifen-Induced Apoptosis in HepG2 Cells.Nutrients · 2022Article
- A Comprehensive Analysis and Anti-Cancer Activities of Quercetin in ROS-Mediated Cancer and Cancer Stem Cells.International journal of molecular sciences · 2022Review
- Combination Anticancer Therapies Using Selected Phytochemicals.Molecules (Basel, Switzerland) · 2022Review
- Nutraceuticals and Cancer: Potential for Natural Polyphenols.Nutrients · 2021Review
- Article
- Manuka honey enhanced sensitivity of HepG2, hepatocellular carcinoma cells, for Doxorubicin and induced apoptosis through inhibition of Wnt/β-catenin and ERK1/2.Biological research · 2021Article
- Quercetin as a Novel Therapeutic Approach for Lymphoma.Oxidative medicine and cellular longevity · 2021Review
- Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health.Cancer medicine · 2020Review
- Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities.Cancer chemotherapy and pharmacology · 2020Review
- Preventive effect of lemon seed flavonoids on carbon tetrachloride-induced liver injury in mice.RSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin, a natural polyphenolic flavonoid compound, can inhibit the growth of several malignant cancers. However, the mechanism still remains unclear. Our previous findings have suggested that quercetin can significantly inhibit HepG2 cell proliferation and induce cell apoptosis in vitro. It can also affect cell cycle distribution and significantly decrease cyclin D1 expression. In this study, we investigated the anti-cancer effect of quercetin on HepG2 tumor-bearing nude mice and its effect on cyclin D1 expression in the tumor tissue. First, the nude murine tumor model was established by subcutaneous inoculation of HepG2 cells, then quercetin was administered intraperitoneally, and the mice injected with saline solution were used as controls. The daily behavior of the tumor-bearing mice was observed and differences in tumor growth and survival rate were monitored. The expression of cyclin D1 in isolated tumor sections was evaluated by immunohistochemistry. We found that HepG2 tumor became palpable in the mice one-week post-inoculation. Tumors in the control group grew rapidly and the daily behavior of the mice changed significantly, including listlessness, poor feeding and ataxia. The mice in quercetin-treated group showed delayed tumor growth, no significant changes in daily behavior, and the survival rate was significantly improved. Finally, we observed increased tumor necrosis and a lighter cyclin D1 staining with reduced staining areas. Our findings thus suggest that quercetin can significantly inhibit HepG2 cell proliferation, and this effect may be achieved through the regulation of cyclin D1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.